Compare MATW & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | RLMD |
|---|---|---|
| Founded | 1850 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 524.9M |
| IPO Year | 1995 | 2012 |
| Metric | MATW | RLMD |
|---|---|---|
| Price | $27.69 | $5.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 305.4K | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | 45.28 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,795,737,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.19 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $21.95 | $0.55 |
| 52 Week High | $30.93 | $8.00 |
| Indicator | MATW | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 34.18 |
| Support Level | $25.33 | $4.06 |
| Resistance Level | $28.57 | $7.28 |
| Average True Range (ATR) | 0.78 | 0.40 |
| MACD | 0.08 | -0.11 |
| Stochastic Oscillator | 78.01 | 18.18 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.